PRGN-3005 UltraCAR-T is a type of multigenic CAR-T cell therapy which utilizes Precigens advanced non-viral gene delivery system

Precigen Inc, a biopharmaceutical company and a wholly owned subsidiary of Intrexon Corporation, has recently confirmed that the first patient has been dosed with PRGN-3005, Precigens first in class investigational therapy using the UltraCAR-T™ therapeutic platform of the company.

Apparently, Precigen's PRGN-3005 ULTRACAR-T is a chimeric antigen receptor T cell therapy produced through non-viral gene delivery and is under investigation for the treatment of patients having advanced, recurrent ovarian, fallopian tube or primary peritoneal cancer that is platinum resistant.

Sources familiar with the matter mentioned that PRGN-3005 could utilize transformative UltraCAR-T therapeutic platform, which is designed to eliminate ex vivo expansion and lower manufacturing time to enable rapid next day UltraCAR-T cells administration subsequently following a non-viral gene transfer. 

Seemingly, PRGN-3005 UltraCAR-T is a type of multigenic CAR-T cell investigational therapy which utilizes advanced non-viral gene delivery system of Precigen, to co-express a membrane-bound interleukin15 chimeric antigen receptor, and a kill switch for better control and precision.

According to President of Precigen, Helen Sabzevari, PhD, this is a vital milestone in company’s efforts to develop a new treatment choice for patients with ovarian cancer. With the initial ovarian cancer patient dosed with PRGN-3005 UltraCAR-T investigational therapy, the company remains committed towards its goal of delivering significant new therapies for solid tumor patients with great unmet need.

Supposedly, conducted in partnership with Fred Hutchinson Cancer Research Center and the University of Washington, the PRGN-3005 UltraCAR-T clinical trial is an open-label and a first in human Phase 1 dosage escalation study to examine the safety and maximal tolerated dosage of PRGN-3005 UltraCAR-T delivered by intravenous infusion or intraperitoneal infusion.

The study population will include patients with advanced stage recurrent primary peritoneal, fallopian tube, ovarian cancer who are platinum-resistant and have progressed despite getting standard of care therapies or are not suitable to receive available therapies with substantial known clinical benefit.

Source Credits: https://www.prnewswire.com/news-releases/precigen-announces-first-patient-dosed-in-phase-1-study-of-prgn-3005-ultracar-t-in-patients-with-advanced-recurrent-platinum-resistant-ovarian-fallopian-tube-or-primary-peritoneal-cancer-300896084.html?tc=eml_cleartime